Program
adagrasib
Also written as “Adagrasib”, “MRTX849” and “Eltrombopag + adagrasib”.
Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Biliary Tract Neoplasms, led by 2 companies.
Drug pageAdagrasib: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 157 open or running | phase 3since Oct 28, 2020 | Dec 18, 2018 | Feb 16, 2028phase 2 · NCT07415031 |
| Zai Labits history only | 10 open or running | phase 1since Jan 13, 2022 | Jan 13, 2022 | none ahead |
Also a collaborator on its studies: Aadi Bioscience, Novartis and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Dec 18, 2018.
- Oct 28, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT04613596 · 626 planned · United States, Argentina, Australia and more
- Dec 19, 2020Named adagrasibINNProposed as its International Nonproprietary Name in WHO's List 124 · before, MRTX849
- Dec 21, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT04685135 · 453 enrolled · United States, Australia, Austria and more
- Mar 2, 2021Phase 3 study in Colorectal NeoplasmsBristol-Myers Squibb · NCT04793958 · 461 enrolled · United States, Argentina, Australia and more
- Jul 6, 2021Phase 1 study in Neoplasm MetastasisBristol-Myers Squibb · NCT04975256 · 7 enrolled · United States
- Dec 1, 2021Phase 1 study in Advanced Solid TumorBristol-Myers Squibb · NCT05178888 · 11 enrolled · United States
- Jan 13, 2022Zai Lab’s first study: phase 1 study in Neoplasm MetastasisNew to Zai LabZai Lab · NCT05263986 · 22 enrolled · China
- Apr 12, 2023Phase 2 study in Neoplasm MetastasisBristol-Myers Squibb · NCT05853575 · 200 enrolled · United States, Brazil, Croatia and more
- Apr 12, 2023Phase 1 study in Neoplasm MetastasisBristol-Myers Squibb · NCT05840510 · 6 enrolled · United States
- Jun 20, 2023Phase 1 study in Healthy AdultsBristol-Myers Squibb · NCT05924152 · 16 enrolled · United States
- Aug 29, 2023Phase 2 study in Biliary Tract NeoplasmsBristol-Myers Squibb · NCT06024174 · 5 enrolled · United States, Australia, Finland and more
- Jan 24, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT06801418 · 160 enrolled · United States
- Mar 7, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06875310 · 630 planned · United States, Argentina, Australia and more
- Feb 11, 2026Phase 2 study in Solid TumorsBristol-Myers Squibb · NCT07415031 · 170 planned · United States, Australia, Belgium and more
- Jul 20, 2026Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT07723118 · 10 enrolled · United States
Ahead
- Feb 16, 2028Primary completion: phase 2 study in Solid TumorsBristol-Myers Squibb · NCT07415031
- Oct 31, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT04613596
- Sep 7, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06875310
TargetBeta
“An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
“GTPase KRas inhibitor”ChEMBL 37, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07723118Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Sep 8, 2026 | 10 |
| NCT07415031Solid Tumors · United States, Australia, Belgium and more | 2 | Recruiting | Bristol-Myers Squibb | Feb 16, 2028 | 170 |
| NCT06875310Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Sep 7, 2029 | 630 |
| NCT06801418Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Jun 19, 2025 | 160 |
| NCT06024174Biliary Tract Neoplasms · United States, Australia, Finland and more | 2 | Terminated | Bristol-Myers Squibb | May 13, 2024 | 5 |
| NCT05924152Healthy Adults · United States | 1 | Completed | Bristol-Myers Squibb | Aug 9, 2023 | 16 |
| NCT05853575Neoplasm Metastasis · United States, Brazil, Croatia and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Oct 30, 2026 | 200 |
| NCT05840510Neoplasm Metastasis · United States | 1 | Terminated | Bristol-Myers Squibb | Dec 27, 2024 | 6 |
| NCT05263986Neoplasm Metastasis · China | 1 | UNKNOWN | Zai Lab | Oct 31, 2023 | 22 |
| NCT05178888Advanced Solid Tumor · United States | 1 | Completed | Bristol-Myers Squibb | Jun 15, 2023 | 11 |
| NCT04975256Neoplasm Metastasis · United States | 1 | Terminated | Bristol-Myers Squibb | Nov 2, 2022 | 7 |
| NCT04793958Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Jan 16, 2026 | 461 |
| NCT04685135Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Dec 30, 2023 | 453 |
| NCT04613596Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Oct 31, 2028 | 626 |
| NCT04330664Neoplasm Metastasis · United States | 1 | Completed | Bristol-Myers Squibb | Jul 29, 2022 | 86 |
| NCT03785249Neoplasm Metastasis · United States, Puerto Rico | 2 | Active, not recruiting | Bristol-Myers Squibb | Jun 23, 2026 | 731 |
How it is read
Names in the registry
- “Adagrasib”, 12 entries
- “MRTX849”, 7 entries
- “Eltrombopag + adagrasib”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Colorectal Neoplasms, 1 study
- Biliary Tract Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.